Moderna Inc
USUSDModerna Inc (XETRA:0QF) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 3. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- modernatx.com
- Relazioni con gli Investitori
- investors.modernatx.com/
- Settore
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede Centrale
- Cambridge, United States
- Gestione
- Stéphane Bancel
- Dipendenti
- 5 800
- Fondata
- 2010
- Azioni in Circolazione
- 399.24 Mln al 2026-07-24
- Flottante
- 372.19 Mln
- Capitalizzazione di Mercato
- 76.88 Mld USD
- Insider
- 7.34%
- Investitori Istituzionali
- 80.46%
- Settore (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma Giuridica
- XTIQ
- ISIN
- US60770K1079
- LEI
- 549300EI6OKH5K5Q2G38
- P/B
- 11.8
- FCF
- −1.24 Mld USD
- Debito
- 591 Mln USDliquidità netta
- Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
- NAV
Descrizione
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| FMR, LLC | 12.99% | 51.86 Mln | 2026-06-30 |
| Blackrock Inc. | 7.66% | 30.6 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 5.81% | 23.21 Mln | 2026-06-30 |
| Capital World Investors | 5.58% | 22.28 Mln | 2026-06-30 |
| Stéphane Bancel (Chief E… | ≈5.56% | 22.22 Mln | 2026-08-06 |
| BAILLIE GIFFORD & CO | 4.56% | 18.21 Mln | 2026-06-30 |
| State Street Corporation | 3.94% | 15.73 Mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 3.9% | 15.58 Mln | 2026-06-30 |
| Growth Fund of America | 3.75% | 14.98 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.84% | 11.33 Mln | 2026-06-30 |
| Geode Capital Management… | 2.43% | 9.71 Mln | 2026-06-30 |
| Morgan Stanley | 2.39% | 9.54 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.29% | 9.15 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.05% | 8.19 Mln | 2026-06-30 |
| Theleme Partners LLP | 2.02% | 8.06 Mln | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.7% | 6.79 Mln | 2026-07-31 |
| Fidelity Securities Fund… | 1.33% | 5.31 Mln | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.3% | 5.19 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.18% | 4.7 Mln | 2026-08-31 |
| AMERICAN FUNDS INSURANCE… | 1.16% | 4.62 Mln | 2026-06-30 |
| VANGUARD WORLD FUND-Vang… | 1.15% | 4.58 Mln | 2026-05-31 |
| HOGE STEPHEN (President) | ≈0.43% | 1.72 Mln | 2026-09-15 |
| KLINGER SHANNON THYME (O… | ≈0.02% | 81 340 | 2026-09-04 |
| MOCK JAMES M (Chief Fina… | ≈0.01% | 59 375 | 2026-09-10 |
| NADER FRANCOIS E. (Direc… | ≈0.01% | 32 781 | 2026-04-30 |
| NABEL ELIZABETH G (Direc… | ≈0% | 19 317 | 2026-04-30 |
| HORNING SANDRA (Director… | ≈0% | 18 585 | 2026-04-30 |
| HUSSAIN SHAH ABBAS (Dire… | ≈0% | 12 066 | 2026-05-01 |
| Robert S. Langer, Jr. | — | — | — |
| Noubar Afeyan (Director) | — | — | 2026-05-21 |
| SAGAN PAUL L (Director) | — | — | 2025-03-03 |
Accedi con Google